Clinical Trials on Metastatic Hepatocellular Carcinoma in India

Total 316 results

Sesen Bio, Inc.

Terminated

Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer

Head and Neck Cancer | Head and Neck Neoplasms | Carcinoma, Squamous Cell | Neoplasms, Squamous Cell | Mouth Neoplasms | Carcinoma, Squamous Cell of Head and Neck

Spain, Germany, Israel, Italy, Poland, United Kingdom, India, Argentina, France, Hungary, Serbia, Croatia, Ukraine, Brazil, Russian Federation, Mexico, Romania, Slovakia
AstraZeneca

Active, not recruiting

A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients (PACIFIC-5)

Carcinoma, Non-Small-Cell Lung

Poland, Taiwan, India, Mexico, Russian Federation, Turkey, China, Korea, Republic of, Philippines, Hong Kong
AstraZeneca

Completed

Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer (KESTREL)

Squamous Cell Carcinoma of the Head and Neck

United States, Canada, France, Italy, Spain, United Kingdom, Poland, Taiwan, Thailand, Vietnam, Belgium, Germany, Korea, Republic of, Brazil, India, Japan, Philippines, Russian Federation, Austria, Ukraine, Greece, Slovakia, Romania
AstraZeneca

Active, not recruiting

Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) (NEPTUNE)

Non Small Cell Lung Carcinoma NSCLC

Denmark, United Kingdom, United States, Poland, Brazil, India, Japan, Mexico, Peru, Russian Federation, Turkey, China, Malaysia, Hong Kong, Korea, Republic of, Chile, Israel, Ukraine, Portugal, Greece, Bulgaria, Philippines, Sweden, A... and more
Eli Lilly and Company

Available

Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

Metastatic Breast Cancer

Australia, Canada, Egypt, India, Italy, Korea, Republic of, Malaysia, Singapore, South Africa, Spain, Switzerland, Taiwan, Thailand, United Kingdom
AstraZeneca

Enrolling by invitation

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab (ROSY-D)

Cancer

United States, France, Italy, Spain, United Kingdom, Canada, Poland, Thailand, Vietnam, Germany, Korea, Republic of, Brazil, Hungary, India, Japan, Russian Federation, China, Malaysia, Australia, Turkey, Ukraine, Bulgaria, Taiwan, Arg... and more
GlaxoSmithKline

Completed

Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma

Carcinoma, Renal Cell

Italy, Argentina, Korea, Republic of, Estonia, Hong Kong, Ukraine, Ireland, Latvia, Pakistan, China, Austria, Greece, New Zealand, Poland, Russian Federation, United Kingdom, Australia, India, Czech Republic, Mexico, Brazil, Chile, ... and more
Novartis Pharmaceuticals

Terminated

Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%

Non-small Cell Lung Cancer (NSCLC)

Japan, Germany, Spain, Italy, France, Thailand, Belgium, Netherlands, India, Malaysia, Taiwan, Australia, Canada, Czechia, Greece, Hong Kong
AstraZeneca

Completed

Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy. (MERMAID-2)

Carcinoma, Non- Small Cell Lung

United States, Canada, France, Italy, Netherlands, Spain, Belgium, Poland, Taiwan, Vietnam, Korea, Republic of, Brazil, Czechia, Hungary, Japan, Peru, Russian Federation, Hong Kong, Israel, Greece, Australia, Singapore, Turkey, India, A...
Pfizer

Completed

A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)

Metastatic Breast Cancer

Korea, Republic of, Serbia, Argentina, Brazil, Japan, Peru, Turkey, United States, Slovakia, Mexico, Philippines, Poland, Romania, Hungary, India, Portugal, South Africa, Latvia, Thailand, Russian Federation, Ukraine, Chile, Czechia, ...
Peregrine Pharmaceuticals

Completed

Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer

Non-Squamous Non-Small Cell Lung Cancer

United States, India, Georgia, Russian Federation, Ukraine
Amgen

Completed

Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Romania, Canada, Korea, Republic of, Philippines, Lithuania, Serbia, Latvia, Estonia, Greece, India, China, Croatia, Mexico, Malaysia, Chile, Brazil
AstraZeneca

Completed

Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer (HORIZON II)

Metastatic Colorectal Cancer

Brazil, Bulgaria, Czech Republic, Korea, Republic of, Poland, United Kingdom, Philippines, China, Germany, Hungary, Argentina, Taiwan, Switzerland, Australia, India
Mateon Therapeutics

Terminated

Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer (FACT)

Anaplastic Thyroid Cancer

United States, India, Belarus, Bulgaria, Egypt, Israel, Italy, Poland, Romania, Russian Federation, Ukraine, United Kingdom
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer (MONALEESA-7)

Advanced Metastatic Breast Cancer

Canada, Italy, Hungary, Taiwan, Turkey, Belgium, Germany, Spain, United States, Singapore, Australia, Korea, Republic of, Hong Kong, Thailand, Lebanon, Bulgaria, France, Russian Federation, Argentina, Brazil, Malaysia, Portugal, Col... and more
Merck Sharp & Dohme LLC

Recruiting

Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)

Lung Neoplasms | Non-Small-Cell Lung Carcinoma

United States, Brazil, Canada, Chile, China, Guatemala, Hong Kong, Hungary, Japan, Korea, Republic of, Malaysia, Mexico, Peru, Russian Federation, South Africa, Taiwan, Thailand, Ukraine, Romania, Dominican Republic, Philippines, ... and more
AstraZeneca

Approved for marketing

Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment

Non Small Cell Lung Cancer (NSCLC)

Taiwan, Thailand, Turkey, Brazil, Philippines, Russian Federation, Romania, Austria, Hungary, Bulgaria, Latvia, India, Argentina, Australia, Estonia, Malaysia, Mexico, Singapore, South Africa
Peregrine Pharmaceuticals

Completed

Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer

Non-small-cell Lung Cancer

United States, India, Georgia, Russian Federation, Ukraine
AstraZeneca
Hutchison MediPharma

Recruiting

Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib (SAVANNAH)

Carcinoma

Denmark, Spain, United States, Taiwan, Vietnam, Canada, Korea, Republic of, Brazil, India, Japan, Italy, Puerto Rico, France, Chile
AstraZeneca

Recruiting

Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC (SAMETA)

Papillary Renal Cell Carcinoma

China, Czechia, Israel, Netherlands, Spain, United Kingdom, Korea, Republic of, Italy, India, Mexico, Turkey, Argentina, Australia, Canada, Germany, Russian Federation, Taiwan, United States, Poland, Brazil, Chile, Hong Kong, Ukraine, Franc... and more
Sanofi

Completed

Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen

Prostate Cancer Metastatic

Australia, Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Czech Republic, Denmark, Finland, Hungary, India, Ireland, Italy, Kazakhstan, Luxembourg, Malaysia, Mexico, Philippines, Poland, Portugal, Romania, Serbia, Singapo... and more
NantCell, Inc.

Completed

QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma

Metastatic Colorectal Cancer

United States, Italy, France, Russian Federation, Spain, Hungary, Poland, Singapore, Hong Kong, India
Pfizer

Completed

Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects (INTORACT)

Renal Cell Carcinoma

France, Belgium, Hungary, Taiwan, United States, Australia, Spain, Hong Kong, Malaysia, Serbia, Argentina, Brazil, Canada, Chile, Colombia, Czech Republic, Germany, India, Italy, Korea, Republic of, Mexico, Netherlands, Poland, Portugal, Russian Federation and more
Eli Lilly and Company

Completed

A Study of Induction and Maintenance Treatment of Advanced Non-squamous Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

United Kingdom, Germany, Poland, Belgium, Spain, Italy, Greece, Australia, Netherlands, Romania, France, India, Finland, Turkey, Portugal
Hoffmann-La Roche

Recruiting

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

Locally Advanced or Metastatic Breast Cancer

France, Belgium, United States, Korea, Republic of, Taiwan, Brazil, China, Italy, Argentina, Jordan, Mexico, Germany, Portugal, Spain, Thailand, United Kingdom, Kenya, Turkey, Hungary, Colombia, India, Oman, Saudi Arabia, Poland, Uganda, United... and more
AstraZeneca
Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo

Active, not recruiting

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer (DB-06)

Advanced or Metastatic Breast Cancer

United States, Belgium, Canada, Denmark, France, Italy, Spain, Hungary, Poland, Taiwan, Russian Federation, Germany, Korea, Republic of, Brazil, Japan, Mexico, United Kingdom, China, Israel, Austria, Australia, Saudi Arabia, Netherl... and more
AstraZeneca

Recruiting

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) (CAPItello-292)

Locally Advanced (Inoperable) or Metastatic Breast Cancer

Spain, Denmark, United States, Korea, Republic of, Germany, Belgium, Vietnam, United Kingdom, France, Japan, Brazil, Canada, China, India, Malaysia, Taiwan, Thailand, Australia, Turkey, Argentina, Poland, Sweden, Italy
Boehringer Ingelheim

Completed

LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy

Carcinoma, Non-Small-Cell Lung

United States, Spain, Taiwan, China, United Kingdom, Denmark, Canada, Korea, Republic of, Germany, Italy, Netherlands, Singapore, Austria, France, Portugal, Greece, India, Mexico, Hungary, Turkey, Argentina, Chile, Ireland
Boehringer Ingelheim

Completed

LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib

Carcinoma, Non-Small-Cell Lung

Austria, Germany, Spain, China, Taiwan, Argentina, Australia, Belgium, Brazil, Finland, France, Hungary, India, Israel, Italy, Korea, Republic of, Mexico, Netherlands, Peru, Poland, Russian Federation, Ukraine, United Kingdom
AstraZeneca
Daiichi Sankyo

Active, not recruiting

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

Breast Cancer; HER2-positive; Metastatic

United States, Belgium, Canada, Denmark, Italy, Spain, Hungary, Taiwan, Turkey, France, Germany, Korea, Republic of, Brazil, India, Japan, Peru, Philippines, United Kingdom, China, South Africa, Israel, Russian Federation, Argentina, ... and more
AstraZeneca

Active, not recruiting

Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer

Poland, India, Thailand, Vietnam, Turkey, Korea, Republic of, Brazil, Czechia, Hungary, Japan, Mexico, Peru, Philippines, Russian Federation
Spectrum Pharmaceuticals, Inc

Completed

Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment

Non-small Cell Lung Cancer

United States, Czechia, India, Brazil, Argentina, Hungary
Eli Lilly and Company

Completed

Pemetrexed and Best Supportive Care Versus Placebo and Best Supportive Care in Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

China, Italy, Australia, Poland, Netherlands, India, Austria, Spain, Bulgaria, United States, Greece, Turkey, Brazil, Croatia, Czech Republic, Germany, Hungary, Korea, Republic of, Romania, Taiwan
Amgen

Completed

Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients

Locally Recurrent and Metastatic Breast Cancer

United States, United Kingdom, Denmark, Poland, Belgium, Hungary, Spain, Austria, France, Australia, Netherlands, Finland, India
Hoffmann-La Roche

Recruiting

A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases

Carcinoma, Non-Small-Cell Lung

Brazil, China, France, Croatia, Greece, Italy, Mexico, Spain, India, Netherlands, Romania, Sweden, Thailand, Lebanon, Turkey, Slovakia, Jordan, Russian Federation, Germany
Bayer

Completed

A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC). (MISSION)

Carcinoma | Non-Small-Cell Lung

Italy, Spain, China, Korea, Republic of, Bulgaria, Turkey, Greece, Philippines, Taiwan, Russian Federation, Hungary, Singapore, France, Netherlands, Sweden, Belgium, United States, Austria, Thailand, Germany, Israel, Poland, Canada, United... and more
Pfizer

Terminated

Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLC

Carcinoma, Non-Small-Cell Lung

United States, Canada, Belgium, Italy, Spain, United Kingdom, Korea, Republic of, Netherlands, Poland, Portugal, Turkey, Taiwan, Germany, Hungary, Brazil, Hong Kong, Singapore, South Africa, China, Austria, Czech Republic, India, Is... and more
AstraZeneca

Active, not recruiting

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) (ORION)

Non-small Cell Lung Cancer NSCLC

United Kingdom, Belgium, United States, Korea, Republic of, Hungary, Japan, Russian Federation, Poland, Ukraine, India, Mexico, Netherlands
Novartis Pharmaceuticals

No longer available

Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC

Non-small Cell Lung Cancer (NSCLC)

United States, Argentina, Korea, Republic of, Hong Kong, Thailand, Mexico, Jordan, Colombia, India, Philippines
Pfizer

Approved for marketing

Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma

Carcinoma, Renal Cell

United States, Netherlands, Canada, Bulgaria, Czech Republic, Hungary, Spain, United Kingdom, Greece, Australia, Belgium, France, Germany, Italy, Panama, Russian Federation, Sweden, Brazil, Taiwan, Argentina, Mexico, Serbia, Thailand, Korea, Republic of and more
Pfizer

Completed

Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Belgium, Bulgaria, Hungary, Spain, Ukraine, Germany, Ireland, Korea, Republic of, Poland, Portugal, Russian Federation, Slovakia, Sweden, Mexico, Serbia, Singapore, Taiwan, Thailand, United Kingdom, Cyprus, Czech Republic, India, Ar... and more
Amgen

Completed

ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Sweden, Belgium, Czechia, Italy, Poland, United States, France, Korea, Republic of, Peru, Philippines, Russian Federation, United Kingdom, China, Canada, Israel, Lithuania, Australia, South Africa, Bulgaria, Romania, Taiwan, Latvia, Serbi... and more
AstraZeneca
Daiichi Sankyo

Recruiting

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (TROPION-Lung10)

Non-Small Cell Lung Cancer

Spain, Italy, Japan, Brazil, Taiwan, Korea, Republic of, Australia, Austria, Canada, Poland, United States, Belgium, United Kingdom, Turkey, Hungary, Germany, India
Novartis Pharmaceuticals

Completed

Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

Canada, Taiwan, United States, Italy, Korea, Republic of, Thailand, Belgium, Germany, Austria, Turkey, Greece, United Kingdom, Colombia, India, Malaysia, Brazil, Spain, Poland, Bulgaria, Australia, Czechia, Lebanon, Netherlands, Russian...
GlaxoSmithKline

Completed

Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer

Metastatic Cervical Cancer | Neoplasms, Uterine Cervix

United States, Germany, Spain, Thailand, Belgium, Italy, Argentina, Canada, Ireland, India, France, Estonia, Mexico
AstraZeneca

Completed

Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC) (MERMAID-1)

Carcinoma, Non-Small-Cell Lung

United States, Canada, Denmark, France, Netherlands, Belgium, Poland, Taiwan, Thailand, Vietnam, Italy, Korea, Republic of, Brazil, Czechia, Hungary, Japan, Russian Federation, Germany, Hong Kong, Spain, Greece, Switzerland, Australia, Isra... and more
Gemin X
Cephalon

Completed

A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Extensive-stage Small Cell Lung Cancer

Canada, United States, United Kingdom, Serbia, Bulgaria, India, Hungary, Czech Republic, Poland, Romania
Eli Lilly and Company

Completed

A Phase 3 Trial of LY900003 Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States, France, Germany, Taiwan, Spain, Belgium, Switzerland, Netherlands, Russian Federation, South Africa, Poland, Hungary, Italy, Norway, India, Sweden, Argentina, United Kingdom, Puerto Rico, Chile, Romania
Poniard Pharmaceuticals

Unknown

Study of Picoplatin Efficacy After Relapse (SPEAR)

Small Cell Lung Cancer

India, Russian Federation, Argentina, Belarus, Bosnia and Herzegovina, Bulgaria, Chile, Croatia, Hungary, Latvia, Montenegro, Poland, Romania, Serbia, Ukraine
mAbxience Research S.L.

Completed

A Study Comparing MB02 and Avastin® in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (STELLA)

Non-small Cell Lung Cancer

Philippines, Hungary, Chile, Mexico, Spain, Serbia, Malaysia, Brazil, Bulgaria, Georgia, Greece, India, Lebanon, Oman, Russian Federation, Thailand, Turkey, Ukraine

Clinical Trials on Metastatic Hepatocellular Carcinoma in India

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ukraine

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations